Cell Signaling – Multimedia

Across a wide variety of cancer types, a protein called KRAS can get hyperactivated and transmit an overload of unwanted growth signals to the cells, causing them to divide and form a tumor.

Antibodies are used in a broad range of research and diagnostic applications for the enrichment, detection, and quantitation of proteins and their modifications.

What if you could get high quality results without the hassle? Our wide range of assay solutions makes it easier to take an orthogonal approach to your cell-based assays, glean more biologically relevant information, and get to breakthroughs faster.

While the shift to 3D cell culture has been under way for the last decade, it is still evolving rapidly to meet the ever growing and dynamic pharmaceutical demand.
Here we provide tips which we deem essential for anyone carrying out 3D cell culture.

Here we take a look at 5 novel approaches to repair diseased and damaged hearts.

We have developed a homogenous bioluminescent assay (GTPase-Glo) system to analyze these proteins in a simple, convenient “add-mix-read” format.

Here we evaluate the ability to detect changes in phosphorylation levels of ERK and CREB following treatment with Aβ using the SH-SY5Y neuroblastoma cell line.

This presentation discusses the details of upstream signaling involved in Akt activation.

In this talk, Matthias Nees discusses the development of cell culture model systems to recapitulate key aspects of cancer progression and to functionally validate biomarkers, target genes, and molecular signaling pathways.

The proteome is the most functional component encoded for in the genome. Advances in proteomic technologies allow comprehensive profiling of of signaling pathways, precise expression of therapeutic targets in tissues and cellular subcompartments, and of metabolomic features that determine likelihood of therapeutic response. Moreover the current paradigm shift in cancer therapy with dramatic and durable responses to antibody and checkpoint therapeutics that trascend tumor genomic profiles further emphasize opportunities to identify novel targets and tailor treatment based on their expression patterns. The potential for personalizing cancer treatment based on proteomic and metabolomic profiles will be presented for epithelial type tumors including lung and pancreatic cancer.